US FTC’s Final Rule On Fake Consumer Reviews ‘Unlocks’ Remedies For Obtaining Civil Penalties

The FTC says its final rule banning fake consumer reviews and testimonials will help to restore its depleted toolbox for obtaining civil penalties. The agency maintains the final rule’s benefits will greatly outweigh costs for honest companies increasingly set back by bad actors in the space.

• Source: Shutterstock (Shutterstock)

The Federal Trade Commission has issued a final rule that prohibits the sale or purchase of fake consumer reviews and testimonials, among other deceptive practices, and restores its authority to seek civil penalties against violators, the agency says.

Published on 14 August, the Trade Regulation Rule on the Use of Consumer Reviews and Testimonials – passed by...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Marketing & Advertising

Asking For More: Supplement MPL Authority For FDA, Agency Results For Congress, Industry

Following Energy and Commerce Health Subcommittee hearing about FDA’s human food and tobacco programs on 10 September, gap between what the trade groups, committee leadership and the FDA each want more of doesn’t appear to be shrinking.

Beauty Brands Not On TikTok Shop ‘Really Missing Out’ – KO-Pack

 

At one year, TikTok Shop conjures the early days of Amazon, representing the ‘Wild West’ of beauty ecommerce, said co-founders of private label and contract manufacturing company KO-Pack at the IBA Cosmetics Convergence Fall 2024 Virtual Symposium, “The Promise and Pitfalls of TikTok Shop.”

Over The Counter: Exploring The Postbiotic Opportunity In Consumer Health, With Kerry’s Sonja Nodland

 
• By 

In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry. 

Kratom Industry Argues FDA Wants To Label All Products As Adverse Events Without Evidence

 

Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.

More from Business

Dermapharm Makes Changes To Turn Around Arkopharma’s Performance

 
• By 

Intensified competition in the dietary supplements market and consumers squeezed by cost-of-living pressures held back sales at Dermapharm's Arkopharma subsidiary in the first half. A leadership change, along with a renewed focus on commercial excellence, is hoped by Dermapharm to turn the business around.

Over The Counter: Exploring The Postbiotic Opportunity In Consumer Health, With Kerry’s Sonja Nodland

 
• By 

In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry. 

Kratom Industry Argues FDA Wants To Label All Products As Adverse Events Without Evidence

 

Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.